563 related articles for article (PubMed ID: 31385295)
1. Influence of PEGylation on PLGA nanoparticle properties, hydrophobic drug release and interactions with human serum albumin.
Samkange T; D'Souza S; Obikeze K; Dube A
J Pharm Pharmacol; 2019 Oct; 71(10):1497-1507. PubMed ID: 31385295
[TBL] [Abstract][Full Text] [Related]
2. Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles.
Partikel K; Korte R; Stein NC; Mulac D; Herrmann FC; Humpf HU; Langer K
Eur J Pharm Biopharm; 2019 Aug; 141():70-80. PubMed ID: 31082511
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
4. Micelle-templated, poly(lactic-
Nabar GM; Mahajan KD; Calhoun MA; Duong AD; Souva MS; Xu J; Czeisler C; Puduvalli VK; Otero JJ; Wyslouzil BE; Winter JO
Int J Nanomedicine; 2018; 13():351-366. PubMed ID: 29391794
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
6. Comparative whole corona fingerprinting and protein adsorption thermodynamics of PLGA and PCL nanoparticles in human serum.
Ndumiso M; Buchtová N; Husselmann L; Mohamed G; Klein A; Aucamp M; Canevet D; D'Souza S; Maphasa RE; Boury F; Dube A
Colloids Surf B Biointerfaces; 2020 Apr; 188():110816. PubMed ID: 31991290
[TBL] [Abstract][Full Text] [Related]
7. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of three-arm block copolymer poly(lactic-
Zhu X; Liu C; Duan J; Liang X; Li X; Sun H; Kong D; Yang J
Int J Nanomedicine; 2016; 11():6065-6077. PubMed ID: 27895480
[TBL] [Abstract][Full Text] [Related]
9. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
10. Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release.
Rietscher R; Czaplewska JA; Majdanski TC; Gottschaldt M; Schubert US; Schneider M; Lehr CM
Int J Pharm; 2016 Mar; 500(1-2):187-95. PubMed ID: 26784983
[TBL] [Abstract][Full Text] [Related]
11. Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles.
Elsewedy HS; Dhubiab BEA; Mahdy MA; Elnahas HM
Drug Deliv; 2020 Dec; 27(1):1134-1146. PubMed ID: 32729331
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug release behavior, mechanism and antimicrobial activity of rifampicin loaded low molecular weight PLGA-PEG-PLGA triblock copolymeric nanospheres.
Gajendiran M; Divakar S; Raaman N; Balasubramanian S
Curr Drug Deliv; 2013 Dec; 10(6):722-31. PubMed ID: 23701139
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional nanoplatform based on star-shaped copolymer for liver cancer targeting therapy.
Gong X; Zheng Y; He G; Chen K; Zeng X; Chen Z
Drug Deliv; 2019 Dec; 26(1):595-603. PubMed ID: 31195837
[TBL] [Abstract][Full Text] [Related]
15. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Characterization of PLGA-PEG Thymoquinone Nanoparticles and Its Cytotoxicity Effects in Tamoxifen-Resistant Breast Cancer Cells.
Ahmad R; Kaus NHM; Hamid S
Adv Exp Med Biol; 2020; 1292():65-82. PubMed ID: 30560443
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer.
Bhattacharya S
Recent Pat Anticancer Drug Discov; 2021; 16(1):84-100. PubMed ID: 33349222
[TBL] [Abstract][Full Text] [Related]
19. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
20. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
Avgoustakis K
Curr Drug Deliv; 2004 Oct; 1(4):321-33. PubMed ID: 16305394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
